Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P trimmed its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,671,011 shares of the company’s stock after selling 241,194 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Roivant Sciences were worth $43,428,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ROIV. WINTON GROUP Ltd lifted its stake in shares of Roivant Sciences by 1.5% in the 4th quarter. WINTON GROUP Ltd now owns 92,526 shares of the company’s stock valued at $1,095,000 after purchasing an additional 1,332 shares during the last quarter. EntryPoint Capital LLC lifted its position in Roivant Sciences by 328.3% in the fourth quarter. EntryPoint Capital LLC now owns 53,443 shares of the company’s stock valued at $632,000 after buying an additional 40,964 shares during the last quarter. United Services Automobile Association boosted its stake in Roivant Sciences by 6.1% during the fourth quarter. United Services Automobile Association now owns 27,494 shares of the company’s stock worth $325,000 after buying an additional 1,588 shares during the period. Vanguard Group Inc. increased its position in shares of Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Roivant Sciences by 11.3% in the 4th quarter. LPL Financial LLC now owns 73,308 shares of the company’s stock valued at $867,000 after acquiring an additional 7,452 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.10.

Insider Activity

In other news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. The trade was a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Venker sold 177,704 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the transaction, the chief operating officer now owns 740,976 shares of the company’s stock, valued at approximately $8,550,863.04. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,573,245 shares of company stock worth $17,079,242. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Stock Up 0.4 %

Shares of ROIV stock opened at $10.48 on Friday. The firm has a 50 day moving average of $10.76 and a two-hundred day moving average of $11.43. The stock has a market capitalization of $7.48 billion, a PE ratio of -69.86 and a beta of 1.26. Roivant Sciences Ltd. has a 52 week low of $9.96 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.